{"altmetric_id":3374918,"counts":{"readers":{"mendeley":3,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:5828023"],"posts_count":1}},"citation":{"abstract":"To quantify the long-term risk of second primary cancers (SCs) in patients diagnosed with Hodgkin's disease (HD) during adolescence or young adulthood.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["F E van Leeuwen","W J Klokman","M B Veer","A Hagenbeek","A D Krol","U A Vetter","M Schaapveld","P van Heerde","J M Burgers","R Somers","B M Aleman"],"doi":"10.1200\/jco.2000.18.3.487","first_seen_on":"2015-02-06T03:20:41+00:00","handles":[],"isbns":[],"issns":["0732-183X"],"issue":"3","journal":"Journal of Clinical Oncology","last_mentioned_on":1212239777,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10653864"],"pmid":"10653864","pubdate":"2000-02-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.","type":"article","volume":"18","mendeley_url":"http:\/\/www.mendeley.com\/research\/longterm-risk-second-malignancy-survivors-hodgkins-disease-treated-during-adolescence-young-adulthoo-9"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3628496,"mean":4.94108381299,"rank":817058,"this_scored_higher_than_pct":63,"this_scored_higher_than":2288436,"rank_type":"exact","sample_size":3628496,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":93856,"mean":8.0669287091792,"rank":24293,"this_scored_higher_than_pct":72,"this_scored_higher_than":68488,"rank_type":"exact","sample_size":93856,"percentile":72},"this_journal":{"total_number_of_other_articles":4898,"mean":8.1866971615275,"rank":2069,"this_scored_higher_than_pct":50,"this_scored_higher_than":2457,"rank_type":"exact","sample_size":4898,"percentile":50},"similar_age_this_journal_3m":{"total_number_of_other_articles":94,"mean":12.720086021505,"rank":59,"this_scored_higher_than_pct":36,"this_scored_higher_than":34,"rank_type":"exact","sample_size":94,"percentile":36}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Postgraduate":1,"Other":2},"by_discipline":{"Medicine and Dentistry":3}}}},"posts":{"wikipedia":[{"title":"ABVD","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=216181084#altmetric_citation_10","license":"public","citation_ids":[3374918],"posted_on":"2008-05-31T13:16:17+00:00","summary":"ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, supplanting the older MOPP protocol.","page_url":"http:\/\/en.wikipedia.org\/?curid=5828023","wiki_lang":"en","author":{"name":"DOI bot","url":"http:\/\/en.wikipedia.org\/wiki\/User:DOI bot"}}]}}